Bayer Shares Face Critical Test as Momentum Falters

The impressive recovery rally that characterized Bayer's stock performance last year appears to be stalling. The Leverkusen-based conglomerate is encountering turbulence in the markets, with technical indicators beginning to flash warning signs. This recent consolidation phase demands a sober reassessment from investors, even as many analysts maintain faith in the company's underlying fundamentals.

Analysts Maintain a Constructive View

Despite the deteriorating technical picture, a positive outlook persists among some market observers. Swiss banking giant UBS has reaffirmed its "Buy" rating for the life sciences group. This confidence is rooted in the expectation of a successful corporate turnaround being executed this year. While the final quarter of 2025 delivered disappointing results, featuring declining revenues and a net loss, UBS strategists project a return to solid earnings per share for 2026.

A Struggle at Key Technical Levels

Examining the price action reveals a notable cooling-off period. The equity has depreciated by approximately eleven percent over the past month. This sell-off pushed the share price to a Friday close of €37.78, breaching the closely watched 100-day moving average, which currently sits at €38.90. Technical analysts frequently interpret a sustained break below this level as an indication of fading bullish momentum. This marks a shift from mid-February, when the stock hit a yearly peak before profit-taking activity commenced.

Should investors sell immediately? Or is it worth buying Bayer?

Upcoming Catalyst in May

In the near term, market focus will center on whether the share price can stabilize within its current range to avert a deeper downward trend. A significant event for fundamental clarity is scheduled for May 12, 2026. On this date, Bayer's management team will present first-quarter results. This report is anticipated to provide crucial evidence on whether the anticipated operational improvements are materializing in the company's financial statements.

Ad

Bayer Stock: New Analysis - 29 March

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

DE000BAY0017 | BAYER | boerse | 69020377 |